Rutika J. Mehta, MD, MPH, discusses the current treatment paradigm in HER2-positive gastric cancer.
Rutika J. Mehta, MD, MPH
Advertisement
Articles by Rutika J. Mehta, MD, MPH
Rutika J. Mehta, MD, MPH, discusses the role of biomarkers in gastric cancer.
Rutika J. Mehta, MD, MPH, discusses how treatment has evolved in recent years for gastric and gastroesophageal junction cancers.
Advertisement
Latest Updated Articles
Dr. Mehta on the Current Treatment Paradigm in HER2-Positive Gastric CancerPublished: September 8th 2020 | Updated:
Dr. Mehta on the Role of Biomarkers in Gastric CancerPublished: August 26th 2020 | Updated:
Dr. Mehta on the Evolution of Treatment in Gastric and GEJ CancersPublished: August 11th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
2
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
3
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
4
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
5